keyword
https://read.qxmd.com/read/38527954/pneumocystis-jirovecii-pneumonia-in-paediatric-acute-lymphoblastic-leukaemia-a-report-from-the-multi-international-clinical-trial-aieop-bfm-all-2009
#1
JOURNAL ARTICLE
Anke Barnbrock, Anja Möricke, Draga Barbaric, Neil Jones, Christa Koenig, Reinhard Moser, Marius Rohde, Christina Salvador, Julia Alten, Sarah Elitzur, Andreas H Groll, Thomas Lehrnbecher
Pneumocystis jirovecii can cause life-threatening pneumonia (PjP), and patients with haematological malignancies are at high risk of this infection. Prophylactic measures have significantly decreased morbidity and mortality, but there is a paucity of contemporary data on the incidence and clinical course of PjP in well-defined and homogenous patient populations, such as children suffering from acute lymphoblastic leukaemia (ALL). In the multi-international trial AIEOP-BFM ALL2009, PjP was diagnosed in six children (incidence 1/1000) and was associated with insufficient prophylaxis in five of them...
March 25, 2024: British Journal of Haematology
https://read.qxmd.com/read/38525380/exploring-nk-cell-receptor-dynamics-in-paediatric-leukaemias-implications-for-immunotherapy-and-prognosis
#2
JOURNAL ARTICLE
Cui Tu, Irina Buckle, Ingrid Leal Rojas, Gustavo Rodrigues Rossi, David P Sester, Andrew S Moore, Kristen Radford, Camille Guillerey, Fernando Souza-Fonseca-Guimaraes
OBJECTIVES: Immunotherapies targeting natural killer (NK) cell receptors have shown promise against leukaemia. Unfortunately, cancer immunosuppressive mechanisms that alter NK cell phenotype prevent such approaches from being successful. The study utilises advanced cytometry to examine how cancer immunosuppressive pathways affect NK cell phenotypic changes in clinical samples. METHODS: In this study, we conducted a high-dimensional examination of the cell surface expression of 16 NK cell receptors in paediatric patients with acute myeloid leukaemia and acute lymphoblastic leukaemia, as well as in samples of non-age matched adult peripheral blood (APB) and umbilical cord blood (UCB)...
2024: Clinical & Translational Immunology
https://read.qxmd.com/read/38514165/hepatic-veno-occlusive-disease-complicated-with-extreme-hyperammonaemia-920-%C3%A2%C2%B5mol-l-treated-with-defibrotide-lactulose-rifampin-and-haemodialysis
#3
JOURNAL ARTICLE
Maciej Kabat, Sarvarinder Gill, Kevin Kim, Karan Omidvari, Robert Lee
Hepatic veno-occlusive disease (VOD)/sinusoidal obstructive syndrome (SOS) is a severe complication that can occur following haematopoietic stem cell transplant (HSCT) with high-intensity conditioning chemotherapy regimens. Severe VOD/SOS, often characterised by multiorgan failure, is associated with a high mortality rate. This case report details the complex clinical course of a male patient in his mid-20s, recently diagnosed with B cell acute lymphoblastic leukaemia, who underwent allogeneic HSCT. Based on the 2023 European Society for Blood and Marrow Transplantation (EBMT) criteria, the patient developed very severe VOD/SOS, prompting immediate treatment with defibrotide...
March 21, 2024: BMJ Case Reports
https://read.qxmd.com/read/38494194/proof-of-concept-of-physiologically-based-pharmacokinetic-modelling-in-paediatric-acute-lymphoblastic-leukaemia
#4
JOURNAL ARTICLE
Thomas Bauch, Georg Hempel
Physiologically based pharmacokinetic (PBPK) modelling is an alternative modelling technique that is increasingly used in pharmacokinetics. Due to its nature, it can be complementarily employed to population pharmacokinetics, especially when it comes to small population size. Here, we report the proof of concept of its application to accurately describe the pharmacokinetics of a recombinant L-asparaginase in paediatric patients with acute lymphoblastic leukaemia. Data from two randomized, double-blind, phase II/III clinical studies (MC-ASP...
March 17, 2024: British Journal of Haematology
https://read.qxmd.com/read/38489859/survival-of-european-adolescents-and-young-adults-diagnosed-with-cancer-in-2010-2014
#5
JOURNAL ARTICLE
Annalisa Trama, Laura Botta, Charles Stiller, Otto Visser, Adela Cañete-Nieto, Ben Spycher, Magdalena Bielska-Lasota, Alexander Katalinic, Claudia Vener, Kaire Innos, Rafael Marcos-Gragera, Keiu Paapsi, Marcela Guevara, Elena Demuru, Seyed Mohsen Mousavi, Marcel Blum, Andrea Eberle, Andrea Ferrari, Alice Bernasconi, Paolo Lasalvia
BACKGROUND: We used the comprehensive definition of AYA (age 15 to 39 years) to update 5-year relative survival (RS) estimates for AYAs in Europe and across countries and to evaluate improvements in survival over time. METHODS: We used data from EUROCARE-6. We analysed 700,000 AYAs with cancer diagnosed in 2000-2013 (follow-up to 2014). We focused the analyses on the 12 most common cancers in AYA. We used period analysis to estimate 5-year RS in Europe and 5-year RS differences in 29 countries (2010-2014 period estimate) and over time (2004-06 vs...
January 24, 2024: European Journal of Cancer
https://read.qxmd.com/read/38488312/practice-guideline-preparation-for-car-t-cell-therapy-in-children-and-young-adults-with-b-acute-lymphoblastic-leukaemia
#6
JOURNAL ARTICLE
Avijeet Kumar Mishra, Saskia Burridge, Macarena Oporto Espuelas, Maeve O'Reilly, Michelle Cummins, Emma Nicholson, Sophie Wheldon, Denise Bonney, Geoff Shenton, David I Marks, Persis J Amrolia, Rachael Hough, Sara Ghorashian
The objective of this guideline, prepared by the ALL subgroup of the Advanced Cell Therapy Sub-Committee of BSBMTCT (British Society of Blood and Marrow Transplantation), is to provide healthcare professionals with practical guidance on the preparation of children and young adults with B-acute lymphoblastic leukaemia from the point of referral to that of admission for CAR T-cell treatment. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate the levels of evidence and to assess the strength of recommendations...
March 15, 2024: British Journal of Haematology
https://read.qxmd.com/read/38480542/nomogram-predictive-models-for-adult-patients-with-acute-lymphoblastic-leukaemia-based-on-real-world-treatment-outcomes
#7
JOURNAL ARTICLE
Yi Chen, Yanxin Chen, Zhengjun Wu, Jiazheng Li, Yan Huang, Xiaomei Peng, Jing Zheng, Yong Wu, Jianda Hu
This study aimed to analyse the characteristics and treatment outcomes of adult patients with acute lymphoblastic leukaemia (ALL) and construct nomogram predictive models for prognosis prediction. Between January 2017 and June 2022, 462 adult patients with ALL were included in this retrospective analysis. Patients' ages ranged from 14 to 84 years. B-cell origin was observed in 82.7% of these patients, while 17.3% of the cases were of T-cell origin. The BCR/ABL1 fusion gene was detected in 32.9% of those with B-ALL...
March 14, 2024: Annals of Hematology
https://read.qxmd.com/read/38479427/refining-risk-stratification-in-paediatric-b-acute-lymphoblastic-leukaemia-combining-ikzf1-plus-and-day-15-mrd-positivity
#8
JOURNAL ARTICLE
Hsi-Che Liu, Ying-Jung Huang, Tang-Her Jaing, Kang-Hsi Wu, Shih-Hsiang Chen, Shih-Chung Wang, Ting-Chi Yeh, Chih-Cheng Hsiao, Te-Kau Chang, Hsiu-Ju Yen, Fang-Liang Huang, Pei-Chin Lin, Jen-Yin Hou, Jiunn-Ming Sheen, Yu-Mei Liao, Tsung-Yen Chang, Yu-Chieh Chen, Shyh-Shin Chiou, Chao-Ping Yang, Ching-Hon Pui, Der-Cherng Liang, Lee-Yung Shih
This study investigates the potential utility of IKZF1 deletion as an additional high-risk marker for paediatric acute lymphoblastic leukaemia (ALL). The prognostic impact of IKZF1 status, in conjunction with minimal/measurable residual disease (MRD), was evaluated within the MRD-guided TPOG-ALL-2013 protocol using 412 newly diagnosed B-ALL patients aged 1-18. IKZF1 status was determined using multiplex ligation-dependent probe amplification. IKZF1 deletions, when co-occurring with CDKN2A, CDKN2B, PAX5 or PAR1 region deletions in the absence of ERG deletions, were termed IKZF1plus ...
March 13, 2024: British Journal of Haematology
https://read.qxmd.com/read/38463129/response-to-apheretic-platelet-transfusion-in-children-of-acute-lymphoblastic-leukemia-receiving-induction-chemotherapy-a-cross-sectional-study-from-bangladesh
#9
JOURNAL ARTICLE
Sushanta Kumar Basak, Mohammad Azmain Iktidar, Romana Chowdhury, Ayesha Khatun, Atiar Rahman, Sonia Shormin Miah, Sheikh Saiful Islam Shaheen, Sudeshna Mazumder
BACKGROUND: Disease and therapy-related hypoproliferative thrombocytopenia is a significant barrier to managing acute lymphoblastic leukaemia (ALL) patients. To reduce the risk of haemorrhage, apheretic platelet transfusion is a modern, effective, and expensive option. Since most ALL patients in Bangladesh have financial constraints, this study can shed light on the magnitude of benefit regarding the effectiveness of apheretic platelet prophylactically and therapeutically in children of ALL receiving induction chemotherapy...
March 2024: Annals of Medicine and Surgery
https://read.qxmd.com/read/38459732/ctla-4-blockade-of-natural-killer-cells-increases-cytotoxicity-against-acute-lymphoid-leukaemia-cells-neda
#10
JOURNAL ARTICLE
Neda Parvini, Mohammad Esmaeil Akbari, Amir Ali Hamidieh, Fardin Fathi, Abbas Ali Amini, Marzieh Ebrahimi, Zakaria Vahabzadeh
OBJECTIVE: There is interest in using cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy to treat blood cancers. Unfortunately, patients with acute lymphoblastic leukaemia (ALL) frequently exhibit resistance to treatment and natural killer (NK) cell exhaustion. This study aims to increase the cytotoxic potency of natural killer cells by using CTLA-4 to block the Nalm-6 leukaemia cell line. MATERIALS AND METHODS: In this experimental study, NK cells were purified from the peripheral blood mononuclear cells (PBMCs) of 10 healthy people and assessed by flow cytometry for purity and viability...
February 1, 2024: Cell Journal
https://read.qxmd.com/read/38452755/epidemiology-and-risk-factors-of-bloodstream-infections-among-adolescents-and-young-adults-with-acute-lymphoblastic-leukaemia-an-11-year-retrospective-cohort-study
#11
JOURNAL ARTICLE
Longlong Xue, Yishu Tang, Liwen Wang, Cong Xu, Qian Cheng, Xin Li
Adolescent and young adults (AYAs) belong to a unique category of patients diagnosed with acute lymphoblastic leukaemia (ALL). Bloodstream infection (BSI) is a leading cause of treatment-related mortality in ALL patients. However, the epidemiology and risk factors for mortality from BSIs in AYA patients remain unclear. In this study, we analysed these aspects in AYAs patients and compared similarities and differences with children (<15 years old) and older adults (>39 years old). We analysed the pathogenic epidemiology, antibiotic resistance and BSI risk factors of 73 children, 180 AYAs, and 110 older adults with ALL in three comprehensive hospitals from January 2010 to August 2021...
April 2024: Clinical and Experimental Pharmacology & Physiology
https://read.qxmd.com/read/38444113/relevance-of-cd20-antigen-expression-among-paediatric-patients-with-b-lineage-acute-lymphoblastic-leukaemia
#12
JOURNAL ARTICLE
Karthik Bommannan, Jhansi Rani Arumugam, Venkatraman Radhakrishnan, Shirley Sundersingh
Literature regarding prognostic relevance of CD20 antigen expression among paediatric B-lineage acute lymphoblastic leukaemia (B-ALL) patients is sparse and contradictory. We analysed clinical laboratory parameters and survival characteristics pertinent to CD20 expression among 224 treatment-naïve paediatric B-ALL patients. 50% patients had CD20 expression (CD20+ B-ALL). There was no difference in the clinical & laboratory presentation and end of induction measurable residual disease (EOI-MRD) status according to CD20 expression...
March 5, 2024: British Journal of Haematology
https://read.qxmd.com/read/38441597/allogeneic-stem-cell-transplantation-is-still-a-highly-curative-therapy-in-adults-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukaemia
#13
JOURNAL ARTICLE
Lijuan Hu, Zongru Li, Sen Yang, Ting Zhao, Wenbing Duan, Yazhen Qin, Jinsong Jia, Jing Wang, Shengye Lu, Hao Jiang, Xiaohui Zhang, Lanping Xu, Yu Wang, Yueyun Lai, Hongxia Shi, Xiaojun Huang, Qian Jiang
The application of tyrosine kinase inhibitors (TKIs) and novel immunotherapies has improved outcomes in patients with Ph + acute lymphoblastic leukaemia (ALL), and the issue of whether there is still a need for stem cell transplantation has become controversial. We performed a retrospective study to explore whether stem cell transplantation still held a place in patients with Ph + ALL if only imatinib and 2nd generation TKIs are available and affordable. A total of 292 patients were included...
March 5, 2024: Annals of Hematology
https://read.qxmd.com/read/38441169/identifying-a-core-protein-signature-of-small-extracellular-vesicles-derived-from-b-cell-precursor-acute-lymphoblastic-leukaemia
#14
JOURNAL ARTICLE
Nathaniel Edward Bennett Saidu, Miriam Aarsund, Eva Sørensen, Maria Stensland, Tuula Anneli Nyman, Aina Ulvmoen, Yunjie Wu, Marit Inngjerdingen
Acute paediatric leukaemia is diagnosed and monitored via bone marrow aspirate assessment of blasts as a measure of minimal residual disease. Liquid biopsies in the form of blood samples could greatly reduce the need for invasive bone marrow aspirations, but there are currently no blood markers that match the sensitivity of bone marrow diagnostics. Circulating extracellular vesicles (EVs) represent candidate biomarkers that may reflect the blast burden in bone marrow, and several studies have reported on the utility of EVs as biomarkers for adult haematological malignancies...
March 2024: Scandinavian Journal of Immunology
https://read.qxmd.com/read/38437908/immune-therapies-of-b-cell-acute-lymphoblastic-leukaemia-in-children-and-adults
#15
REVIEW
David Kegyes, Gabriel Ghiaur, Anamaria Bancos, Ciprian Tomuleasa, Robert Peter Gale
B-cell acute lymphoblastic leukaemia (B-cell ALL) is a common haematologic cancer in children and adults. About 10 percent of children and 50 percent of adults fail to achieve a histological complete remission or subsequently relapse despite current anti-leukaemia drug therapies and/or haematopoietic cell transplants. Several new immune therapies including monoclonal antibodies and chimeric antigen receptor (CAR)-T-cells are proved safe and effective in this setting. We review data on US Food and Drug Administration (FDA)-approved immune therapies for B-cell ALL in children and adults including blinatumomab, inotuzumab ozogamicin, tisagenlecleucel, and brexucabtagene autoleucel...
March 2, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38432257/high-dose-methotrexate-pharmacokinetics-and-its-impact-on-prognosis-of-paediatric-acute-lymphoblastic-leukaemia-patients-a-population-pharmacokinetic-study
#16
JOURNAL ARTICLE
Xiaoxiao Chen, Jing Li, Liting Yu, Wenting Hu, Jiaoyang Cai, Zhuo Wang, Changcheng Chen, Xin Zhang, Yangyang Xie, Kefei Wu, Yixiao Mo, Jihui Chen, Shuhong Shen
This study delivers a comprehensive evaluation of the efficacy and pharmacokinetics of high-dose methotrexate (HDMTX) in a large cohort of Chinese paediatric acute lymphoblastic leukaemia patients. A total of 533 patients were included in the prognostic analysis. An association was observed between lower steady-state MTX concentrations (<56 μmol/L) and poorer outcomes in intermediate-/high-risk (IR/HR) patients. Subgroup analysis further revealed that this relationship between concentrations and prognosis was even more pronounced in patients with MLL rearrangements...
March 3, 2024: British Journal of Haematology
https://read.qxmd.com/read/38432068/faster-clinical-decisions-in-b-cell-acute-lymphoblastic-leukaemia-a-single-flow-cytometric-12-colour-tube-improves-diagnosis-and-minimal-residual-disease-follow-up
#17
JOURNAL ARTICLE
Benjamin Lebecque, Joevin Besombes, Louis-Thomas Dannus, Marie De Antonio, Victoria Cacheux, Victoria Grèze, Valentin Montagnon, Lauren Veronese, Andrei Tchirkov, Olivier Tournilhac, Marc G Berger, Richard Veyrat-Masson
Assessing minimal residual disease (MRD) in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) is essential for adjusting therapeutic strategies and predicting relapse. Quantitative polymerase chain reaction (qPCR) is the gold standard for MRD. Alternatively, flow cytometry is a quicker and cost-effective method that typically uses leukaemia-associated immunophenotype (LAIP) or different-from-normal (DFN) approaches for MRD assessment. This study describes an optimized 12-colour flow cytometry antibody panel designed for BCP-ALL diagnosis and MRD monitoring in a single tube...
March 3, 2024: British Journal of Haematology
https://read.qxmd.com/read/38420726/first-complete-remission-favours-haploidentical-haematopoietic-stem-cell-transplantation-with-post-transplant-cyclophosphamide-over-cord-blood-transplantation-in-acute-lymphoblastic-leukaemia
#18
JOURNAL ARTICLE
Tomoyasu Jo, Tomoaki Ueda, Yu Akahoshi, Tadakazu Kondo, Naoyuki Uchida, Masatsugu Tanaka, Hirohisa Nakamae, Noriko Doki, Shuichi Ota, Masashi Sawa, Hiroyuki Ohigashi, Yumiko Maruyama, Nobuyuki Takayama, Tetsuya Nishida, Nobuhiro Hiramoto, Yuta Katayama, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Yasuyuki Arai
To assess the benefits of HLA-haploidentical haematopoietic stem cell transplantation using post-transplant cyclophosphamide (PTCy-haplo) relative to those of umbilical cord blood (UCB) transplantation in acute lymphoblastic leukaemia (ALL), we analysed 1999 patients (PTCy-haplo, 330; UCB, 1669), using the nationwide Japanese registry. PTCy-haplo was associated with a significantly higher relapse rate, but lower non-relapse mortality, which results in overall survival and disease-free survival, comparable to those of UCB...
February 29, 2024: British Journal of Haematology
https://read.qxmd.com/read/38406525/primary-renal-leukaemia-in-a-young-adult-male-as-an-extramedullary-presentation-of-t-cell-acute-lymphoblastic-leukaemia
#19
Punit Jain, Poonam Jain, Robert S Ohgami, Veena Pawar, Kunal Sehgal, Pradnya Chaudhari, Ravindra Nikalji, Tejinder Singh, Vipin Khandelwal, Sanjay Khare, Vaishali Lokhande, Ashwathy Haridas, Laxman Jessani, Kanika Khandelwal
Primary renal involvement by T lymphoblasts is rare among adults with T acute lymphoblastic leukaemia. We report a 28-year-old man presenting with acute renal failure due to infiltration by T lymphoblasts and his response to paediatric-inspired modified BFM-90 protocol. The patient achieved an initial complete remission (CR) but developed central nervous system relapse. He achieved CR2 with cranial irradiation and intrathecal chemotherapy. He underwent a haploidentical transplant in CR2 and remains in remission post-transplant day 330...
February 2024: EJHaem
https://read.qxmd.com/read/38385580/t-myeloid-mixed-phenotype-acute-leukaemia-harbouring-tlx3-bcl11b-with-tlx3-activation
#20
JOURNAL ARTICLE
Giovanni A Botten, Yuannyu Zhang, Franklin Fuda, Prasad Koduru, Olga K Weinberg, Tamra L Slone, Ruifang Zheng, Kathryn E Dickerson, Jeffrey R Gagan, Weina Chen
T/myeloid mixed phenotype acute leukaemia (MPAL) is a rare aggressive acute leukaemia with poorly understood pathogenesis. Herein, we report two cases of T/myeloid MPAL harbouring BCL11B-associated structural variants that activate TLX3 (TLX3::BCL11B-TLX3-activation) by genome sequencing and transcriptomic analyses. Both patients were young males with extramedullary involvement. Cooperative gene alterations characteristic of T/myeloid MPAL and T-lymphoblastic leukaemia (T-ALL) were detected. Both patients achieved initial remission following lineage-matched ALL-based therapy with one patient requiring a lineage-switched myeloid-based therapy...
February 22, 2024: British Journal of Haematology
keyword
keyword
165285
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.